Colonic Neoplasms
Conditions
Keywords
Immunoscore Adjuvant Prospective Colon
Brief summary
Immunoscore Colon Test (ICT) will be applied on tumor samples from curative surgery. In the Multidisciplinary Meeting (MM) evaluating the participant adjuvant strategy, a first decision will be taken, based on the participant medical record only. ICT will then be disclosed and the MM will take a second decision. The aim of the study is to observe if the ICT result modifies the treatment decision.
Detailed description
On previous studies, Immunoscore Colon test identified subgroups of stage II and III colon cancer patients whose Chemotherapy could be adjusted. The study hypothesis is that Immunoscore Colon Test will modify the therapeutic decision in MM. With Alpha and Beta at 5% and p0=10% modification rate, the participating investigators need to include 280 participants, 140 in each cohort (stage II and stage III). Participants will have tumor samples from their curative surgery tested with Immunoscore Colon. When the patients are evaluated in MM, a first therapeutic decision will be taken before disclosing the test result. ICT result will then be communicated and a second decision will be taken.
Interventions
DIAGNOSTIC_TESTImmunoscore Colon Test
Immunoscore Colon is a CE-marked in-vitro diagnostic test, allowing the quantification of CD3 and CD8 positive cells in formalin-fixed paraffin-embedded (FFPE) tissue samples of primary colon cancer. The test uses immunohistochemistry, digital pathology techniques and a dedicated software.
Sponsors
HalioDx
UNICANCER
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Masking description
Immunoscore Colon Test Result will be disclosed in Multidisciplinary Meeting only after the first therapeutic decision
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Cytologically/histologically proven colon adenocarcinoma * non-metastatic cancer * Stage II or III adenocarcinoma * Surgical resection of primitive tumor within 6 weeks of multidisciplinary meeting * No macroscopic or microscopic proof of residual disease during surgery (R0 margins) * Available surgical material: FFPE tumor samples * Post-operative adjuvant chemotherapy considered during multidisciplinary meeting * Age ≥18 years * Eastern Cooperative Oncology Group (ECOG) performance status ≤2 * Patient having signed a written informed consent prior to any trial specific procedures * Patient affiliated to the social security system or equivalent
Exclusion criteria
* Other invasive cancer within 5 years of the colon cancer diagnosis, except for adequately treated basal cell carcinoma or squamous cell skin carcinoma or in sity cervical carcinoma * Patients for which adjuvant chemotherapy is contra-indicated * Any previous systemic or loco regional anticancer therapy for the studied colon cancer (e.g. neoadjuvant therapy) * Patient enrolled or planned to be enrolled in another clinical trial that may influence the therapeutic decision * Any psychological, social or geographical issue that may hinder the patient's understanding of the study or the study conduct * Person deprived of liberty or under the authority of a legal guardian * Person unable to understand the study or to comply with the protocol procedures
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Modification rate of adjuvant therapeutic strategy | At the multidisciplinary meeting, up to 6 weeks after the cancer surgery | Modifications of adjuvant therapy, type and/or duration |
Countries
France
Outcome results
None listed